| 000 | 01491cam a2200289 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032030.0 | ||
| 008 | 180814s2017 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aGift | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.34.Ph.D.2017.Ra.D | ||
| 100 | 0 | _aRasha Mahmoud Hassan Rashied | |
| 245 | 1 | 0 |
_aDesign and synthesis of novel triphenylethylenes with diverse biological activities / _cRasha Mahmoud Hassan Rashied ; Supervised Ashraf Hassan Abadi , Nermin Salah Ahmed |
| 246 | 1 | 5 | _aتصميم و تشييد نظائر جديدة ثلاثية الفينيل ايثيلين ذات أنشطة بيولوجية متنوعة |
| 260 |
_aCairo : _bRasha Mahmoud Hassan Rashied , _c2017 |
||
| 300 |
_a205 Leaves : _bcharts , facsimiles ; _c30cm |
||
| 502 | _aThesis (Ph.D.) - German University - Faculty of Postgraduate Studies and Scientific Research - Department of Pharmaceutical Chamistry | ||
| 520 | _aTamoxifen (TAM), a non-steroidal triphenylethylene SERM, is considered to be the firstline endocrine therapeutic agent used for treating ER- positive breast cancer. It reduces the risk of recurrence and death when used as adjuvant therapy in early stage or in metastatic cancer | ||
| 700 | 0 |
_aAshraf Hassan Abadi , _eSupervisor |
|
| 700 | 0 |
_aNermin Salah Ahmed , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aShimaa _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c67041 _d67041 |
||